April 2007

PharmaEngine, Inc. 智擎生技製藥股份有限公司

(4162.TWO)

Investor Meeting Credit Suisse

C. Grace Yeh, Ph.D. President & CEO

Sept. 9, 2016

www.pharmaengine.com

2

PEP503 / NBTXR3

Korea MFDS accepted the submission of NDA (May 10, 2016)

Began marketing & sales in Taiwan

2016 Taipei Biotech Award (Go-Global Gold Medal Award )

CHMP positive opinion on MAA (July 22, 2016)

Company Operation

Expanded organization

Incorporated PharmaEngine Europe Sarl (Paris, France)

2016 Company of the Year Gold Award (Taiwan Bio Industry Organization)

ONIVYDE® (PEP02, MM-398, nal-IRI)

Ongoing enrollment of global pivotal study in soft tissue sarcoma

US FDA approved IND application in prostate cancer

Successful preliminary results from phase I/II trial in head & neck cancer

Highlights

Name：PharmaEngine, Inc. (智擎生技製藥股份有限公司)

Established：August 2002 (Operated since Feb. 2003)

Main field：Oncology

Lead Product: ONIVYDE®, Taiwan & US approval ( Oct. 22, 2015 )

Major investors : TTY Biopharm, National Development Fund

Chairman：Jeffrey Suen (孫致中)

President & CEO：C. Grace Yeh, Ph.D. (葉常菁)

Taiwan stock code：4162.TWO

Address：11F, 10 Minsheng E. Road, Sec. 3, Taipei 104, Taiwan

Subsidiary: PharmaEngine Europe Sarl (Paris, France)

Website : http://www.pharmaengine.com

Company Profile

3

4

Major Shareholders

Shareholder Number of Shares Percentage (%)

TTY Biopharm Co., Ltd. 19,701,275 19.30%

National Development Fund,

Executive Yuan 15,686,156 15.36%

Dr. Grace Yeh 4,341,194 4.25%

Center Laboratory Inc. 3,855,848 3.78%

Labor Retirement Fund 2,001,000 1.96%

CTBC Bank Co., Ltd in custody for

Forever One Investment Co., Ltd. 1,482,000 1.45%

Indus Asia Pacific Master Fund, Ltd. 900,000 0.88%

Mercuries Life Insurance Co., Ltd. 779,000 0.76%

Chiang Ching-Kuo Foundation for

International Scholarly Exchange 700,000 0.69%

HSBC Global Investment Funds - Asia

ex Japan Equity Smaller Companies 661,000 0.65%

Total 50,107,473 49.08%

*Updated in April 2016

2003 ~ 2007

2008 ~ 2009

2010 ~ 2013

History and Milestones

- Began operation

- In-licensed PEP02

- Started PEP02 phase I

- Red Herring Asia 100 award

- Started two PEP02 phase 2

- ASCO presentation

- Taipei Biotech Award

- Completed phase 2 gastric cancer in Europe and Asia

- Completed phase 2 pancreatic cancer in US and Taiwan - Out-licensed PEP02 - Started PEP02 (MM-398) global phase 3 pancreatic cancer (NAPOLI-1) - Initial public offering on Taiwan Gretai market (4162:TWO) - In-licensed PEP503 and PEP06 - Achieved enrollment goal of NAPOLI-1

- Phase 3 (NAPOLI-1) top-line data announced

- MM-398 NDA and MAA to US FDA, EMA, TFDA

- MAA accepted by EMA - Priority Review designated by US FDA - Set Up PharmaEngine Europe Sarl (Subsidiary) - ONIVYDE approvals in Taiwan and US - NDA application accepted by Korea MFDS - CHMP positive opinion of MAA

2014 ~ 2016

5

2010 ~ 2013

Drug Discovery Drug Development Marketing & Sales

Phase I Phase II Phase III Pre-Clinical Approval Market

CMO Partners

CRO Partners

Target Validated Target Lead

In-license Partners

PharmaEngine

Out-license Partners Hospitals &

organizations

No Research Development Only (NRDO)

Business Model NRDO & Networked Pharma

Contract Manufacturing

Organizations

Contract Research

Organizations

6

Networked Pharma

7

Created in 2016

8

Senior Management Team

C. Grace Yeh, Ph.D. - Founder, President & CEO

- Ph.D., Immunology, Medical U. of South Carolina, Charleston, SC, USA

- Blond McIndoe Center of Transplantation Biology, England; INSERM, France; T Cell Sciences,

CytoMed, Leukosite, Millennium (Cambridge, MA, USA)

Hubert Chan, MD, Ph.D.

- Vice President, Clinical & Regulatory Affairs

- MD, Chung Shan Medical School, Taichung, Taiwan; Ph.D., Pathobiology, U. of Minnesota, USA

- Certified Medical Oncologist, Cancer Centers; National Institute of Cancer Research, Tainan, Taiwan

Chishing Chang, CPA

- Vice President, Finance & Administration

- Master degree of Accounting, National Taiwan University, Taipei, Taiwan

- Certified Public Accountant (CPA); TTY Biopharm, MasterLink Securities, Sampo Securities

Alain Herrera, MD

- Head, Corporate Development; Managing Director, PharmaEngine Europe

- MD, Pitié-Salpétrière Hospital, Faculty of Medicine, Paris, France

- Alain Oncology Consulting, Global Oncology Business Strategy & Development, Sanofi, Paris, France; Chiron, Pierre Fabre, Roger Bellon, CNRS

Armand de Gramont, Ph.D. - Vice President, Translational Science

- Ph.D. in Cellular Biochemistry at Pierre et Marie Curie University, Paris, France

- Laboratory of Molecular and Cellular Biology, National Institutes of Health (NIH), USA; Head of the

New Drugs Evaluation Laboratory, Lausanne University Hospital, Lausanne, Switzerland

9

Scientific and Clinical Advisors

Scientific Advisory Board

Prof. Aimery de Gramont

- Head of Internal Medicine in Oncology,

French-British Institute Hospital, Paris, France

- Expert in gastrointestinal cancer (FOLFIRI, FOLFOX)

- Sponsor of the colorectal (PEPCOL) cancer study

Prof. David Cunningham

- Head of GI and Lymphoma units, Royal Marsden Hospital,

Sutton, UK

- Chief PI in gastric cancer phase II (PEP0206) study

Prof. Margaret Tempero

- Deputy Director, UCSF Helen Diller Family Comprehensive

Cancer Center, USA

- Participated in pancreatic phase II (PEP0208) study

Prof. Paul A. Bunn

- Prof., Univ. of Colorado Cancer Center, USA

- Expert in lung cancer

- Participated in the lung animal studies of PEP02

Prof. Li-Tzong Chen

- Director, National Institute of Cancer Research, Taiwan

- Expert in gastrointestinal cancer

- Participated in phase I, II, and III studies of PEP02

PharmaEngine Europe Sarl

Managing Director: Alain Herrera, MD

Address: 18 Rue du Dragon, 75006 Paris, France

Increase the source of in-licensing opportunities

Enhance the existing collaboration with Nanobiotix and scientific / clinical advisors

Establish closer relationship with European companies, CROs, and regulatory agencies

Apply government or EU grants to fund European-based development projects

10

Core Competence

PharmaEngine

Project evaluation &

licensing Cancer market

SWOT analysis

Development strategy & execution

Scale up & manufacturing

design Cooperation with oncology

experts

Clinical trial design & execution

Compliance with global regulations

Financial risk management

11

12

Product Mechanism Partner Start Territory Stage

PEP02 (MM-398)

ONIVYDE

Topo 1 Inhibitor

(Anti-cancer)

Merrimack

Pharmaceuticals (Nasdaq: MACK)

April 2003,

Sept. 2005,

May, 2011

Asia & Europe

(licensing-out)

US FDA

TFDA

Approval

PEP503 (NBTXR3)

Radiotherapy

Enhancer

(Anti-cancer)

Nanobiotix S.A (FP: NANO)

Aug. 2012 Asia-Pacific

(licensing-in)

Pivotal

PEP06 (NCE)

Novel mechanisms

(Anti-cancer)

Guangzhou BeBetter

Medicine

Technology

Jan. 2013 Worldwide (excluding China)

(licensing-in)

Drug

discovery

Pipeline and Partnership

(Irinotecan liposome injection)

13

ONIVYDE

安能得

Taiwan FDA & US FDA approvals (Oct. 22, 2015)

Included as category 1 recommendation in the NCCN clinical practice

guidelines (March 2016)

CHMP positive opinion on Marketing Authorization Application from

EMA (July 22, 2016)

14

Significance

The FIRST US FDA approved cancer drug in Taiwan, and the TFDA

approved it before the US FDA.

Onivyde is the FIRST cancer drug developed from preclinical to

regulatory approval in Taiwan.

Onivyde is the FIRST treatment in post-gemcitabine setting showing

a survival benefit in metastatic pancreatic cancer patients.

ONIVYDE (Irinotecan Liposome Injection, PEP02, MM-398, nal-IRI)

CPT-11

SN-38

Irinotecan (CPT-11) is a broad spectrum anti-cancer drug by blocking DNA

replication. It is approved for colorectal cancer with peak sales > US$1 billion.

ONIVYDE is a liposome formulation of irinotecan with sustained release profile

and preferential tumor accumulation (Enhanced Permeability and Retention

effect) and site-specific activation.

15

(CPT-11)

New Formulations of Irinotecan

New Formulations of Irinotecan, SN-38, or Camptothecin

Very few liposome drugs are approved

Project Company Formulation Stage

NKTR-102 Nektar, USA Pegylated irinotecan Phase 3

HA-irinotecan Alchemia, Australia Hyaluronic acid irinotecan Phase 3

CRLX101 Cerulean, USA Nanoparticle-camptothecin Phase 2

CPX-1 Celator, USA Liposome irinotecan-floxuridine Phase 2

NK-012 Nippon Kayaku, Japan Polymeric micelle SN-38 Phase 2

EZN-2208 Enzon, USA Pegylated SN-38 Phase 2

LE-SN38 NeoPharm, USA Liposome SN-38 Phase 2

AR-67 Arno Therapeutics, USA Camptothecin analogue Phase 2

IHL-305 Yakult/Terumo, Japan Liposome irinotecan Phase 1

Technical barriers

• Encapsulation & release

• Stability

• Scalability

16

• Liposomal doxorubicin (Doxil, Caelyx, Myocet)

• Liposomal daunorubicin (DaunoXome)

• Liposomal vincristine (Marqibo)

• Liposomal amphotericin B (AmBisome)

• Liposomal morphine (DepoDur)

Encapsulation efficiency > 95%, and optimal in vitro and in vivo release profile.

Completed process development to a scale of 1,000 vials per batch for GMP-

compliant production with 3-year stability data at 2- 8C.

Transferred manufacturing process to Merrimack, and they scaled up the

process to 5,000 vials per batch for the global phase 3 study, and more for

commercial launch.

Product Characteristics & Manufacturing

17

CRC 2nd-line

PIST-CRC-01

Solid Tumor PEP0201

Solid Tumor PEP0202

PEP0203

Brain

2nd-line (recurrent gliomas)

CRC 2nd-line PEPCOL

Pancreatic

2nd-line

NAPOLI-1

Pancreatic 2nd-line

PEP0208

Gastric

2nd-line PEP0206

GERCOR

NHRI UCSF

Phase I

Phase II

Phase III

Clinical Development

Ewing’s

sarcoma (Pediatric bone

cancers)

SPOC

18

> 700 patients treated with Onivyde in the clinical trials

Clinical Development Path

PEP0206 Randomized, Ph II in GAC

vs. CPT-11 vs. docetaxel iv, q3 weeks

ORR, PK, PGx

PEP0208 Ph II in PDAC iv, q3 weeks OS3m, PGx

PEP0203 Ph I, dose escalating

iv, q3 weeks + weekly HDFL, D1, D8

MTD, PK, PGx

PEP0201 Ph I, dose escalating

iv, q3 weeks MTD, PK study

PIST-CRC-01 Ph I, dose escalating

in mCRC iv, q2 weeks

MTD, PK, PGx

PEPCOL Randomized, Ph II in mCRC

FUPEP vs. FOLFIRI-1 or-3 iv, q2 weeks

ORR, PGx

NAPOLI-1 Randomized, Ph III in PDAC

vs. 5-FU/LV vs. FUPEP iv, q2 or q3 weeks

OS, PK, PGx

19

20

NAPOLI-1*

An open label, randomized phase 3 study of MM-398

with or without 5-Fluorouracil/Leucovorin (5-FU/LV),

versus 5-FU/LV in Patients with Metastatic Pancreatic

Cancer

Principal Investigator: Daniel D. von Hoff, M.D., F.A.C.P

TGen, University of Arizona, Mayo Clinic and Scottsdale Healthcare

*NAPOLI: Nanoliposomal irinotecan

Wang-Gillam, A., et al., Lancet, 387: 545-557, 2016

Phase 3 (NAPOLI-1) Updated Data Shows ONIVYDE® Combination Regimen

Increased One Year Survival by 63% in Metastatic Pancreatic Cancer

One year overall survival estimates of 26%

A well-defined safety and tolerability profile

CA19-9 levels are associated with the treatment effect

21

NAPOLI-1 Data Demonstrates ONIVYDE® Regimen Maintains

Quality of Life While Improving Overall Survival in Patients with

Metastatic Pancreatic Cancer

Methodology :

A total of 154 patients (ONIVYDE in combination with 5-FU and leucovorin,

n=71; 5-FU and leucovorin, n=83) comprised the population for this analysis.

Results:

ONIVYDE combination regimen were able to maintain quality of life over 12

weeks and there were no significant differences versus the 5-FU and

leucovorin-treated patients in quality of life response despite the addition of a

second chemotherapeutic agent.

25

Projected Cancer Deaths (2010-2030)

24

Front line treatment

Treatment Approval Global Sales / $US

Gemcitabine (GEM)

(Gemzar® , Eli Lilly ) 1996 US FDA 2 billion (2007)

Erlotinib + GEM

(Tarceva® , Roche) 2005 US FDA 400 million (2013)

Abraxane + GEM

(Abraxane® , Celgene) 2013 US FDA 960 million (2015)

1994 1998 2002 2006 2013 2015

Gemcitabine Erlotinib + GEM Abraxane + GEM

Post-Gem treatment

ONIVYDE + 5-FU/LV

Approved first line treatment

ONIVYDE + 5-FU/LV is the FIRST treatment in post-gemcitabine setting

showing a survival benefit in this aggressive disease.

Pancreatic Cancer Landscape

25

Product Company /

Partner

Mechanism

of Action

Design Patient

type & No.

Data Development

status (press

release date)

TH-302

(evofosfamide)

Threshold

/ Merck KGaA

Hypoxia-

activated

drug

Phase 3, TH-

302 + gem vs.

placebo + gem

(MAESTRO)

1st line, n =

693

HR = 0.84, p =

0.0589

Terminated

(12/7/2015)

Ruxolitinib Incyte /

Novartis

JAK1/JAK2

inhibitor

Phase 3, Rux +

capecitabine vs.

capecitabine

(JANUS 1)

2nd line, n =

318, CRP-

high

No sufficient

level of efficacy

in planned

interim analysis

Terminated

(2/11/2016)

90Y-

clivatuzumab

Immunomedics Radioimmu

no-

conjugate

to MUC1

Phase 3, 90Y-Cl

+ low gem vs.

placebo + low

gem (PANCRIT-

1)

3rd line, n =

334

No sufficient

level of efficacy

in planned

interim analysis

Terminated

(3/14/2016)

Algenpantucel

-L

NewLink

Genetics

Cancer

vaccine

expressing

alpha-gal

Phase 3,

Algenpantucel-

L vs. standard

of care

(IMPRESS)

Resected, n

= 722

OS = 27.3 m vs.

30.4 m

Terminated

(5/9/2016)

Necuparanib

(M402)

Momenta

Pharmaceuticals

Heparan

sulfate-like

mimetic

Phase 2, M402

+ Abraxane

+gem vs.

Abraxane +gem

1st line, n =

180, 120

randomized

before

termination

No sufficient

level of efficacy

in planned

interim futility

analysis

Terminated

(8/4/2016)

Recent Failures in Advanced

Pancreatic Cancer (12/2015 - 8/2016)

26

Ref: Merrimack conference call in Jan. 2016

ONIVYDE Market Potential

Merrimack launched ONIVYDE in the US on October 26, 2015

US pricing

Onivyde is priced at ~ US$1,620 per vial.

3-4 vials every two weeks, monthly costs ~ US$11,200.

With an average four-month regimen, per patient treatment ~US$43,000.

US sales (net product revenues)

Q4 2015 (2 months): $4.3 million, Q1 2016 : $10.0 million, Q2 : $12.9 million

18,500 potential post-gemcitabine patients may receive treatment

of Onivyde plus 5-FU/LV.

Potential US peak sales of post-gemcitabine pancreatic cancer:

~ US$800 million

MACK conference calls on Aug. 4, 2016

US Sales

27

Commentaries of ONIVYDE

Published online, Nov. 22, 2015

…. few treatment options

currently exist for patients

who have progressed on

first-line gemcitabine-

based therapy …. Hence,

a confirmed survival

benefit in this population

of patients with an unmet

clinical need is especially

exciting.

Published, Sep, 2015

Second-line therapy of

pancreatic cancer has to be

considered in terms of risk

benefit for the patient…... MM-

398 when available in all

countries may be the best

option for second-line treatment

of these patients.

Published online, Apr. 14, 2015

Management of metastatic pancreatic

cancer: Current treatment options and

potential new therapeutic targets Francesco Sclafani, Ridhima Iyer, David Cunningham,

Naureen Starling∗The Royal Marsden NHS Foundation

Trust, London and Surrey, UK

…… it is likely that, based on

the results of this phase III

trial, MM-398 will be granted

formal approval by the

regulatory agencies and soon

become an established

alternative treatment option in

the second line setting of

metastatic PDA.

28

ONIVYDE® as Category 1 Treatment Option in

the 2016 NCCN Guidelines

A category 1 classification represents the highest

level of evidence and uniform NCCN consensus

that the intervention is appropriate.

30

Indication Development Stage

Preclinical Phase I Phase II Phase III NDA

Pancreatic cancer

(Post-Gem) Approved

Pancreatic cancer

(Front-line) Ongoing Data in 2017

Small cell lung cancer

(Second-line) Planning Start in 2016

Colorectal cancer

(Second-line, DOUBLIRI) Ongoing Started in 2015

Ewing's sarcoma

(Pediatric bone tumor) Ongoing Data in 2016

Brain cancer

(Recurrent glioma, CED) Ongoing Data in 2016

Breast cancer

(Metastatic) Ongoing Data in 2016

Colorectal cancer

(Front-line, with anti-EGFR) Ongoing Started in 2016

30

Life Cycle Management

Merrimack corporate overview in July 2016

Potential future development as a combination backbone with

targeted therapy and immuno-oncology therapy

2003

31

2011

2014

US$220 million +

Tiered royalty rate based on the net sales in Europe and Asia

US$970 million

(including US$46.5 million, sublicense revenue to PEI)

Financial Transactions

2015

2016

US$32 billion

US$3 million

Shire acquired Baxalta

(May 2016)

PharmaEngine is eligible to receive up to US$266.5 million plus tiered royalty,

so far received US$48 million

32

Payment Terms

1) Licensing

milestone

US$220 million

(Merrimack)

plus US$46.5

million

(Baxalta)

Upfront US$10 million (May 2011)

Development

& Regulatory

milestone

US$5 million (Feb.2012, phase III 1st patient in)

US$7 million (Sep.2014, amend Agreement with MACK)

US$5 million (April 2015, Completed NDA Submission to US FDA )

US$11 million (June 2015, MAA Acceptance by EMA )

US$10 million (May 2016, Korea MFDS accepted submission NDA )

(Future milestone payment: US$88.5 million)

Sales

Milestone

Based on reaching certain net sales in Europe and Asia

(Future milestone payment: US$130 million)

2) Royalty Tiered royalty rate based on the net sales in Europe and Asia

3) Others All future development costs reimbursed by Merrimack.

Product sales in Taiwan belong to PharmaEngine.

ONIVYDE Licensing Deal

33

PEP503

(Crystalline Hafnium Oxide, NBTXR3)

34

Nanobiotix is a spin-off from the State University of New York (SUNY)

at Buffalo and was incorporated in 2003.

More than 50 employees and is based in Paris, France.

IPO in Oct. 2012. (FP: NANO)

Exclusive license agreement for Asia Pacific region executed in

August 2012, Nanobiotix is eligible for US$57 million and up to double

digit royalty, so far paid US$3 million to Nanobiotix.

Licensing Partner-Nanobiotix

PEP503 (Crystalline Hafnium Oxide)

Crystalline

HfO2 coating

RT dose (Gy)

Pro

babili

ty

10 20 30 40 50 60 70 80

1

0.5

0

CureAdverse eventTherapeutic window

standard

radiotherapywith

NanoXray

RT dose (Gy)

Pro

ba

bility

10 20 30 40 50 60 70 80

1

0.5

0

CureAdverse eventTherapeutic window

Maximal Tolerated Dose Maximal Tolerated Dose

35

PEP503 (NBTXR3) is a nanoparticle formulation of hafnium oxide crystal for the

local treatment of tumors to enhance the efficacy of radiotherapy.

NBTXR3 has been classified in the EU as class III medical device.

Efficacy Evaluation of Phase 1 STS

36

The recommended volume for the pivotal study is 10%.

Intra-tumor Bioavailability

3D visualization demonstrated the persistence over time and optimal

bioavailability of NBTXR3 during all sessions of RTx.

37

Global Pivotal (Phase II/III) Study

Population: Patients with soft tissue sarcoma of the

extremity and trunk wall

End points

Complete pathological

response rate (pCR)

Tumor shrinkage rate and

operability

Progression free survival

(local and distant)

Amputation rate

Study Design

Stratification Population:

myxoid liposarcomas vs others

* Two-arms, randomized, active-controlled, multi-center, and open-label

trial

R 1:1

Study Arm (78 pts):

NBTXR3 + RT (50 Gy – 2 GyF)

Comparator Arm (78 pts):

RT alone (50 Gy – 2 GyF)

156 patients

Target Population

♦ Locally advanced soft tissue sarcoma of the extremity and trunk wall

♦ All grades

♦ Candidate to radiotherapy + surgery (ESMO guideline)

a) Primary tumor or,

b) Relapsed tumor, localized out of previously irradiated area

38 CONFIDENTIAL

Phase I/II H&N Cancer Study Design

Efficacy of PEP503 in H & N Cancer Study

Safety of PEP503 in H & N Cancer Study

42

2016 2017 2018 2019 2020

Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3

Q4

Soft tissue sarcoma

Pivotal Trial

(Nanobiotix, PharmaEngine) Global

Head & neck cancer

Phase I/II (Nanobiotix)

France

Liver cancer Phase I/II

(Nanobiotix) EU

Rectal cancer Phase I/II

(PharmaEngine) Taiwan

Prostate cancer

Phase I

(Nanobiotix) US

PEP503 Development Timeline

Pivotal phase II/III trial in STS, it is the final step before registration (CE mark).

US FDA approved IND in prostate cancer (Jan. 2016).

PharmaEngine expands the clinical applications in rectal and head & neck cancers.

PEP06

(New Chemical Entity)

with

New Projects Under Evaluation

43

Hallmarks of Cancer

44

45

2015 2016 2017 2018

Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4

PEP06 Discovery Preclinical Phase 1

New Projects Preclinical, Phase 1, or Phase 2

PharmaEngine holds worldwide rights of PEP06 with the exception of China,

while BeBetter keeps the respective rights in China.

Filed a patent application for new drug candidates of PEP06

Evaluation of new projects ongoing

New Projects Development Timeline

46

Product Indication Development stage

Research Pre-

clinical Phase 1 Phase 2 Phase 3 NDA

PEP02 (MM-398) (Irinotecan liposomal

injection)

ONIVYDE®

Pancreatic cancer (post-gem)

Approved

Pancreatic cancer (Front-line) Ongoing

Small cell lung cancer (Second-line)

Planning Planning

Colorectal cancer (Second-line)

Ongoing

Ewing's sarcoma (Pediatric Solid Tumors)

Ongoing

Brain cancer (Recurrent Gliomas)

Ongoing

Breast cancer (Metastatic)

Ongoing

PEP503 (NBTXR3) (Crystalline hafnium

oxide)

Soft tissue sarcoma (Nanobiotix, PharmaEngine) Pivotal Trial

Head & neck cancer (Nanobiotix) Ongoing

Liver cancer (Nanobiotix) Ongoing

Rectal cancer (PharmaEngine) Ongoing

Prostate cancer (Nanobiotix) Planning

PEP06 (New Chemical Entity)

Solid tumor Ongoing 46

Portfolio Status

2011 2012 2013 2014 2015 2016 H1

47

2011 2012 2013 2014 2015 2016H1

Profit after tax (NTD,000)

285,707

48,987

123,592

394,022

165,000

117,800

EPS

4.01

-1.23

1.23

3.87

1.62

0.58

2015 dividend：Cash NTD2 & stock NTD2

Revenue Performance

US

Global Collaboration

48

EU China & Asia